118 related articles for article (PubMed ID: 27885740)
1. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
4. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
5. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V; Eckstein M; Hartmann A; Stöhr R
Methods Mol Biol; 2023; 2684():283-291. PubMed ID: 37410241
[TBL] [Abstract][Full Text] [Related]
8. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
[TBL] [Abstract][Full Text] [Related]
9. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
Shibata N; Cho N; Koyama H; Naito M
Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
11. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
12. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Mahe M; Dufour F; Neyret-Kahn H; Moreno-Vega A; Beraud C; Shi M; Hamaidi I; Sanchez-Quiles V; Krucker C; Dorland-Galliot M; Chapeaublanc E; Nicolle R; Lang H; Pouponnot C; Massfelder T; Radvanyi F; Bernard-Pierrot I
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29463565
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
Casadei C; Dizman N; Schepisi G; Cursano MC; Basso U; Santini D; Pal SK; De Giorgi U
Ther Adv Med Oncol; 2019; 11():1758835919890285. PubMed ID: 31803255
[TBL] [Abstract][Full Text] [Related]
14. Novel molecular targets for urothelial carcinoma.
Faltas BM; Karir BS; Tagawa ST; Rosenberg JE
Expert Opin Ther Targets; 2015 Apr; 19(4):515-25. PubMed ID: 25633079
[TBL] [Abstract][Full Text] [Related]
15. Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.
Huang Q; Mitsiades I; Dowst H; Zarrin-Khameh N; Noor AB; Castro P; Scheurer ME; Godoy G; Mims MP; Mitsiades N
NPJ Precis Oncol; 2023 Nov; 7(1):123. PubMed ID: 37980380
[TBL] [Abstract][Full Text] [Related]
16. A selective Fibroblast Growth Factor Receptor 1/2 PROTAC degrader with antitumor activity.
Kong Y; Zhao X; Wang Z; Yuan S; Chen S; Lou S; Ma S; Li Y; Wang X; Ge Y; Li G; Yang H; Zhao M; Li D; Zhang H; Tan W; Wang J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38647531
[TBL] [Abstract][Full Text] [Related]
17. Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis.
Lombardi B; Ashford P; Moya-Garcia AA; Rust A; Crawford M; Williams SV; Knowles MA; Katan M; Orengo C; Godovac-Zimmermann J
Oncotarget; 2017 Nov; 8(61):102898-102911. PubMed ID: 29262532
[TBL] [Abstract][Full Text] [Related]
18. Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized.
Kamatkar N; Levy M; Hébert JM
Mol Ther Nucleic Acids; 2019 Sep; 17():530-539. PubMed ID: 31357131
[TBL] [Abstract][Full Text] [Related]
19. RNAi technology targeting the
Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
[TBL] [Abstract][Full Text] [Related]
20. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK; Grivas P; Gupta S; Dizman N; Zengin Z; Valderrama BP; Rodriguez-Vida A; Roghmann F; Sevillano Fernandez E; Matin SF; Loriot Y; Sridhar SS; Sonpavde G; Fleming MT; Lerner SP; Bellmunt J; Master V; Tripathi A; Davis K; van Veenhuyzen D; Weng R; Daneshmand S
Eur Urol; 2024 Apr; ():. PubMed ID: 38580518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
